
EMRIS Pharma
Developing topical treatments to prevent and treat skin toxicities from cancer therapies.
About
EMRIS Pharma is developing a first-in-class topical solution to prevent skin toxicities associated with targeted cancer therapies, particularly EGFR inhibitors. Their innovation aims to improve patients' quality of life and treatment compliance by blocking anti-cancer drugs in the skin without interfering with the therapy. This addresses the significant unmet need of severe skin side effects experienced by 80%-90% of patients treated with these drugs.
Similar companies
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Shares Life Sciences, Biotech
AI-powered patient-centric drug simulations to accelerate and de-risk drug development.
Shares Life Sciences, Clinical Trials
AI-powered blood test for early cancer detection and subtyping.
Shares Life Sciences, Biotech
Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.
Shares Life Sciences, HealthTech
Omnix Medical is developing a novel platform for advanced wound care management.
Shares Life Sciences, HealthTech
Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.
Shares Life Sciences, Biotech
Key facts
At-a-glance profile data
- Website
- emris-pharma.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 7
- Total funding
- -
- Business model
- B2B
Tech stack
Detected on emris-pharma.com, last scanned 15 Oct 2026. Run your own scan
- Frontend
- jQuery
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
Frequently asked
Is EMRIS Pharma trustworthy and reputable?
StartupHub's Data Trust & Reputation score for EMRIS Pharma is 57 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How many employees does EMRIS Pharma have?
EMRIS Pharma has approximately 7 people on record.
